Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
Santiago González-SantiagoCristina SauraEva CiruelosJosé Luis AlonsoPilar de la MorenaMarta Santisteban EslavaMaria Isabel Gallegos SanchoAlicia de LunaElsa DalmauSonia ServitjaManuel Ruiz BorregoJosé Ignacio ChacónPublished in: Breast cancer research and treatment (2020)
This real-world analysis shows that neoadjuvant pertuzumab, trastuzumab, and chemotherapy achieve comparable or even higher rates of tpCR than those seen in clinical trials. The pCR benefit is higher in HR-negative tumors. The assessment of rCR by MRI showed the highest ability for predicting pCR. In addition, this neoadjuvant strategy confers an acceptable safety profile.